Artikel ; Online: Tumoral melanosis after immunotherapy with pembrolizumab - a response sign mimicking melanoma.
2020 Band 26, Heft 10
Abstract: Tumoral melanosis is a rare histopathological finding characterized by aggregates of melanophages, in the absence of melanocytes, usually observed in sites of regressed melanocytic lesions, including melanoma. A 72-year-old woman with a history of a ... ...
Abstract | Tumoral melanosis is a rare histopathological finding characterized by aggregates of melanophages, in the absence of melanocytes, usually observed in sites of regressed melanocytic lesions, including melanoma. A 72-year-old woman with a history of a completely excised melanoma on her right arm (T3bN0M0, Stage IIb) presented with clinically-evident regional lymph node metastasis. This was treated with right axillary lymphadenectomy. Subsequently, a 2-centimeter blue-colored patch over the excision scar was identified, along with a blue nodule within the posterior aspect of the same arm, consistent with in-transit metastases. Additional metastases on the right hilar region of the lungs were detected by PET/CT. Hence, the patient began immunotherapy with pembrolizumab. After three months, a second PET/CT revealed a complete response, but the patient maintained the blue-colored patch previously observed. Given the discrepancy between the clinical and metabolic response she underwent a skin biopsy; histological examination showed findings compatible with tumoral melanosis resulting from complete regression of a metastatic lesion. In cases of metastatic melanoma under immunotherapy with anti-PD1 agents, especially pembrolizumab, tumoral melanosis has been anecdotally associated with tumor regression and favorable treatment response. The patient has been maintained on pembrolizumab, accomplishing 15 cycles, and has had a complete response to date. |
---|---|
Mesh-Begriff(e) | Aged ; Antibodies, Monoclonal, Humanized/adverse effects ; Biopsy ; Diagnosis, Differential ; Female ; Humans ; Immunotherapy/adverse effects ; Lymph Node Excision ; Lymphatic Metastasis ; Melanoma/diagnosis ; Melanoma/secondary ; Melanoma/surgery ; Melanosis/diagnosis ; Melanosis/etiology ; Skin Neoplasms/pathology |
Chemische Substanzen | Antibodies, Monoclonal, Humanized ; pembrolizumab (DPT0O3T46P) |
Sprache | Englisch |
Erscheinungsdatum | 2020-10-15 |
Erscheinungsland | United States |
Dokumenttyp | Case Reports ; Journal Article |
ZDB-ID | 2026239-5 |
ISSN | 1087-2108 ; 1087-2108 |
ISSN (online) | 1087-2108 |
ISSN | 1087-2108 |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.